AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2547709 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg in grapefruit juice)
Number of subjects: 34
Study 2547709 — intervention group
Group type: COMPARATOR
Intervention: Placebo (grapefruit juice)
Number of subjects: 34
Study 899844 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) treatment at doses of 200, 400, or 600 mg per day
Number of subjects: 0
Study 899844 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPZ) treatment
Number of subjects: 0
Study 31972796 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography-based macular atrophy (MA) at Month 24
Number of subjects: 28
Study 31781387 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-only (EXO; 12 weeks of aerobic exercise and isocaloric diet)
Number of subjects: 50
Study 31781387 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-only (DIO; 8 weeks of very low energy diet (VLED 600 kcal/day) followed by a 4-week weight maintenance diet)
Number of subjects: 50
Study 31781387 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise (DEX; 12 weeks of aerobic exercise in parallel with 8 weeks of VLED (800 kcal/day) followed by a 4-week weight maintenance diet)
Number of subjects: 50
Study 27825272 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg twice daily for five days
Number of subjects: 140
Study 27825272 — intervention group
Group type: COMPARATOR
Intervention: Purified urinary FSH starting with a dose of 75 IU
Number of subjects: 140
Study 25282200 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring group (SMS intervention)
Number of subjects: 49
Study 25282200 — intervention group
Group type: COMPARATOR
Intervention: No-monitoring group (control)
Number of subjects: 49
Study 23450804 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone 100 mg
Number of subjects: 45
Study 23450804 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen 650 mg
Number of subjects: 45
Study 21252245 — intervention group
Group type: EXPERIMENTAL
Intervention: GHR+phosphate
Number of subjects: 44
Study 21252245 — intervention group
Group type: EXPERIMENTAL
Intervention: GHR+alendronate
Number of subjects: 44
Study 21252245 — intervention group
Group type: COMPARATOR
Intervention: GHR alone
Number of subjects: 44
Study 19903594 — intervention group
Group type: EXPERIMENTAL
Intervention: Positioning pillow
Number of subjects: 124
Study 16387515 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandages applied using alternative techniques
Number of subjects: 1
Study 15621556 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Cesarean Section (CS)
Number of subjects: 0
Study 15621556 — intervention group
Group type: COMPARATOR
Intervention: Started Vaginal Birth (VB)
Number of subjects: 0
Study 15621556 — intervention group
Group type: COMPARATOR
Intervention: Planned Cesarean Section (CS)
Number of subjects: 0
Study 15621556 — intervention group
Group type: COMPARATOR
Intervention: Planned Vaginal Birth (VB)
Number of subjects: 0
Study 10638531 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision-support system (Group A)
Number of subjects: 29
Study 10638531 — intervention group
Group type: COMPARATOR
Intervention: Pre-existing understanding of the guidelines and/or written resources (Group B)
Number of subjects: 29
Study 9323798 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (300 IU of eopoetin alpha s.c. per kg body weight three times a week for four weeks)
Number of subjects: 30
Study 9323798 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 9323798 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO group
Number of subjects: 30
Study 8439113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ondansetron
Number of subjects: 349
Study 8439113 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 349
Study 8439113 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 349
Study 8439113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study 8439113 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of ondansetron (1 mg, 4 mg, 8 mg)
Number of subjects: 349
Study 2904116 — intervention group
Group type: EXPERIMENTAL
Intervention: Propoxyphene (Darvon), 100 mg q.i.d.
Number of subjects: 5
Study 2904116 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (Tylenol) with 30 mg codeine, two tabs, q.i.d.
Number of subjects: 5
Study 31249902 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-task Walking Group (STWG)
Number of subjects: 105
Study 31249902 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task Walking Group (DTWG)
Number of subjects: 105
Study 31249902 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogy Walking Group (AGWG)
Number of subjects: 105
Study 31249902 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 105
Study 30423178 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based sleep hygiene intervention (four face-to-face sessions)
Number of subjects: 2841
Study 30423178 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational material)
Number of subjects: 2841
Study 30423178 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory-based sleep hygiene intervention
Number of subjects: 2841
Study 27246677 — intervention group
Group type: EXPERIMENTAL
Intervention: Short bouts of structured physical activity (SBS-PA)
Number of subjects: 291
Study 27246677 — intervention group
Group type: COMPARATOR
Intervention: Unstructured free playtime (UPA)
Number of subjects: 291
Study 25100231 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives and quality feedback
Number of subjects: 143
Study 25100231 — intervention group
Group type: COMPARATOR
Intervention: Feedback alone
Number of subjects: 143
Study 25100231 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical assistance
Number of subjects: 143
Study 22777333 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRI + bevacizumab
Number of subjects: 60
Study 22777333 — intervention group
Group type: COMPARATOR
Intervention: sequential IRIS + bevacizumab
Number of subjects: 60
Study 20471302 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Contour Tonometry (DCT) with daily disposable hydrogel contact lens in situ
Number of subjects: 46
Study 20471302 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Contour Tonometry (DCT) without daily disposable hydrogel contact lens
Number of subjects: 46
Study 17185423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2.2 g DHA and 1.1 g EPA/day)
Number of subjects: 72
Study 17185423 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 72
Study 17185423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 72
Study 17185423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil and olive oil
Number of subjects: 72
Study 15218329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-carnitine (20 mg/kg dry body weight three times weekly after haemodialysis) for 16 weeks
Number of subjects: 26
Study 15218329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11532473 — intervention group
Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 22
Study 11532473 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched individuals)
Number of subjects: 22
Study 11532473 — intervention group
Group type: COMPARATOR
Intervention: Idiopathic hirsutism group
Number of subjects: 22
Study 9817488 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors
Number of subjects: 10691
Study 9817488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10691
Study 7921533 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg daily
Number of subjects: 26
Study 7921533 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 20 mg daily
Number of subjects: 26
Study 3132028 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg alprenolol twice daily
Number of subjects: 33
Study 3132028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 4558306 — intervention group
Group type: EXPERIMENTAL
Intervention: beclomethasone dipropionate aerosol
Number of subjects: 38
Study 4558306 — intervention group
Group type: COMPARATOR
Intervention: prednisolone
Number of subjects: 38
Study 29448922 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily text messages and supportive App
Number of subjects: 60
Study 29448922 — intervention group
Group type: COMPARATOR
Intervention: Control (no text messages or supportive App support)
Number of subjects: 60
Study 28139347 — intervention group
Group type: EXPERIMENTAL
Intervention: OPV0 (Oral Polio Vaccine at birth)
Number of subjects: 3031
Study 28139347 — intervention group
Group type: COMPARATOR
Intervention: NoOPV0 (No Oral Polio Vaccine at birth)
Number of subjects: 3031
Study 26444883 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Learning
Number of subjects: 270
Study 26444883 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 270
Study 23192905 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot orthoses with medial arch support and metatarsal pad
Number of subjects: 94
Study 21240688 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation and botulinum toxin type A
Number of subjects: 6
Study 21240688 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin type A alone
Number of subjects: 6
Study 18458040 — intervention group
Group type: EXPERIMENTAL
Intervention: One course of bleomycin, etoposide, and cisplatin (BEP) chemotherapy
Number of subjects: 382
Study 18458040 — intervention group
Group type: COMPARATOR
Intervention: Retroperitoneal lymph node dissection (RPLND)
Number of subjects: 382
Study 16921009 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention (monthly telephone contact and information/referral services)
Number of subjects: 703
Study 16921009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no case management intervention)
Number of subjects: 703
Study 12688109 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate nasal spray (400 micrograms daily)
Number of subjects: 106
Study 12688109 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 106
Study 10647072 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (5 mg/kg fat-free mass)
Number of subjects: 20
Study 9283216 — intervention group
Group type: EXPERIMENTAL
Intervention: Sairei-to (TJ-114) for 2 years
Number of subjects: 101
Study 9283216 — intervention group
Group type: COMPARATOR
Intervention: No drug for 2 years (Control)
Number of subjects: 101
Study 8421165 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent vaccine
Number of subjects: 0
Study 8421165 — intervention group
Group type: COMPARATOR
Intervention: Bivalent CR influenza A (Bi A) followed by monovalent B (Mono B) vaccine
Number of subjects: 0
Study 8421165 — intervention group
Group type: COMPARATOR
Intervention: Monovalent B (Mono B) followed by bivalent CR influenza A (Bi A) vaccine
Number of subjects: 0
Study 8421165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3896660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 50
Study 3896660 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 1000 mg daily (200 mg 3-times daily and 400 mg at night)
Number of subjects: 50
Study 31743110 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 200
Study 31743110 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 200
Study 30036385 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (CVR) containing oestrogen
Number of subjects: 120
Study 26820652 — intervention group
Group type: EXPERIMENTAL
Intervention: TargetPrint ER
Number of subjects: 6694
Study 26820652 — intervention group
Group type: EXPERIMENTAL
Intervention: TargetPrint PgR
Number of subjects: 6694
Study 26820652 — intervention group
Group type: EXPERIMENTAL
Intervention: TargetPrint HER-2
Number of subjects: 6694
Study 23850410 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesic regimen (periarticular injection of 30cc 0.5% bupivacaine, 10mg MSO4, 15 mg ketorolac and multimodal analgesics including oxycodone, tramadol, ketorolac; narcotics as needed)
Number of subjects: 36
Study 23850410 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with hydromorphone
Number of subjects: 36
Study 22823904 — intervention group
Group type: EXPERIMENTAL
Intervention: myo‐inositol and folic acid
Number of subjects: 100
Study 22823904 — intervention group
Group type: COMPARATOR
Intervention: folic acid
Number of subjects: 100
Study 20362386 — intervention group
Group type: EXPERIMENTAL
Intervention: RALP with median fibrous raphe reconstruction (MFRR)
Number of subjects: 107
Study 20362386 — intervention group
Group type: COMPARATOR
Intervention: Standard anastomosis without posterior reconstruction
Number of subjects: 107
Study 18484552 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 17
Study 15603850 — intervention group
Group type: EXPERIMENTAL
Intervention: LDCT
Number of subjects: 3318
Study 15603850 — intervention group
Group type: COMPARATOR
Intervention: CXR
Number of subjects: 3318
Study 12968395 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (44 micrograms/ml of depigmented, polymerized allergen extract)
Number of subjects: 45
Study 12968395 — intervention group
Group type: COMPARATOR
Intervention: Group B (10 times less than Group A)
Number of subjects: 45
Study 12968395 — intervention group
Group type: COMPARATOR
Intervention: Group C (no specific immunotherapy)
Number of subjects: 45
Study 10429005 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 10
Study 10429005 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 10
Study 8743522 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 107
Study 1993639 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 72
Study 1993639 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 72
Study 1993639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 6083597 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxy-3-methylglutaric acid (HMGA) 1 g three times a day orally for 4 weeks
Number of subjects: 0
Study 6083597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30880072 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alpelisib 200 mg once a day plus olaparib 200 mg twice a day (dose level 3)
Number of subjects: 34
Study 30880072 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alpelisib and olaparib
Number of subjects: 34
Study 29456049 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-aortic balloon counterpulsation (IABC) used in 39 participants.
Number of subjects: 136
Study 29456049 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome of in-hospital mortality, postoperative acute myocardial infarction (AMI), acute kidney injury (AKI), or stroke.
Number of subjects: 136
Study 29456049 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measured using the EuroQol 5-dimensional questionnaire (EQ5D).
Number of subjects: 136
Study 29456049 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative AMI, AKI, or stroke.
Number of subjects: 136
Study 29456049 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality.
Number of subjects: 136
Study 29456049 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month mortality.
Number of subjects: 136
Study 26984349 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant thiamine
Number of subjects: 51
Study 26984349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 24692441 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 0
Study 24692441 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 0
Study 22555869 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. pethidine plus EMLA cream (group A)
Number of subjects: 0
Study 22555869 — intervention group
Group type: COMPARATOR
Intervention: i.v. pethidine plus placebo hydrating cream (group B)
Number of subjects: 0
Study 20533146 — intervention group
Group type: EXPERIMENTAL
Intervention: IBF training course
Number of subjects: 241
Study 20533146 — intervention group
Group type: COMPARATOR
Intervention: Control group (other courses)
Number of subjects: 241
Study 18035190 — intervention group
Group type: EXPERIMENTAL
Intervention: GLY+RSG (glyburide 10 or 20 mg plus rosiglitazone 8 mg)
Number of subjects: 245
Study 18035190 — intervention group
Group type: COMPARATOR
Intervention: GLY+PBO (placebo)
Number of subjects: 245
Study 17551661 — intervention group
Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate
Number of subjects: 0
Study 17551661 — intervention group
Group type: COMPARATOR
Intervention: fluticasone propionate alone
Number of subjects: 0
Study 15094936 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP)
Number of subjects: 254
Study 15094936 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 254
Study 15094936 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 254
Study 15094936 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor VIII concentrates with von Willebrand factor (vWF)
Number of subjects: 254
Study 15094936 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogens and platelet transfusion
Number of subjects: 254
Study 15094936 — intervention group
Group type: COMPARATOR
Intervention: Preoperative treatment
Number of subjects: 254
Study 15094936 — intervention group
Group type: COMPARATOR
Intervention: Retrospective group (no preoperative correction)
Number of subjects: 254
Study 10699742 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg CuSO4
Number of subjects: 26
Study 10699742 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg Cu glycine chelate (CuG)
Number of subjects: 26
Study 10699742 — intervention group
Group type: COMPARATOR
Intervention: Placebo (washout period)
Number of subjects: 26
Study 10699742 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper supplementation (7 mg/d)
Number of subjects: 26
Study 10699742 — intervention group
Group type: EXPERIMENTAL
Intervention: (Cu,Zn)SOD activity
Number of subjects: 26
Study 10699742 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance to hemolysis
Number of subjects: 26
Study 9095564 — intervention group
Group type: EXPERIMENTAL
Intervention: One 20 mg controlled-release oxycodone tablet
Number of subjects: 22
Study 9095564 — intervention group
Group type: COMPARATOR
Intervention: Two 10 mg controlled-release oxycodone tablets
Number of subjects: 22
Study 8252504 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term addition of cyproterone acetate to buserelin (2 weeks)
Number of subjects: 0
Study 8252504 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous addition of cyproterone acetate to buserelin
Number of subjects: 0
Study 8252504 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 0
Study 3101709 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (50 micrograms, reduced to 20 or 10 micrograms in case of side effects), administered 3 to 7 times per week by subcutaneous route for 2 to 6 weeks.
Number of subjects: 0
Study 31453826 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory recall activities with positive reinforcement
Number of subjects: 22
Study 31453826 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive reinforcement
Number of subjects: 22
Study 31433523 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS)
Number of subjects: 20
Study 31433523 — intervention group
Group type: COMPARATOR
Intervention: Sham HD-tDCS (placebo)
Number of subjects: 20
Study 27481206 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant EPO (48,000 IU), administered intravenously 17 times during 24 weeks
Number of subjects: 52
Study 27481206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 27481206 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant EPO (48,000 IU)
Number of subjects: 52
Study 26057782 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU daily
Number of subjects: 26
Study 26057782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 23167274 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 42
Study 23167274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 21818132 — intervention group
Group type: EXPERIMENTAL
Intervention: 20‐ms Pattern Scan Laser (Pascal) panretinal laser photocoagulation (PRP)
Number of subjects: 22
Study 19689235 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 19689235 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study 19689235 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0
Study 19689235 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 0
Study 19689235 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0
Study 19689235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16202499 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE) with gentle air-blowing (g)
Number of subjects: 24
Study 16202499 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Bond (GB) with gentle air-blowing (g)
Number of subjects: 24
Study 16202499 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (LP) with gentle air-blowing (g)
Number of subjects: 24
Study 16202499 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental adhesive SSB-200 (SSB) with gentle air-blowing (g)
Number of subjects: 24
Study 16202499 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE) with strong air-blowing (s)
Number of subjects: 24
Study 16202499 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Bond (GB) with strong air-blowing (s)
Number of subjects: 24